News - Abzena

Filter by year

Filter by topic

Abzena appoints Matthew LeClair as SVP and Site Head of San Diego Operations

Cambridge, UK and San Diego, CA, 3 August 2020 – Abzena, a leading Partner Research Organization (PRO) for biopharmaceutical outsourced solutions from concept to clinic and into GMP manufacturing has announced the appointment of Matthew LeClair as Senior Vice President (SVP) and Site Head of its San Diego Operations. With more than 29 years’ experience in the […] Read more

Abzena Receives Growth Capital Investment from Newly Launched Biospring Partners

Cambridge, UK, Bristol, PA and San Diego, CA — 28 July 2020 — Abzena, a leading global partnership research organization providing integrated discovery, development and manufacturing of biologics and antibody drug conjugates (ADCs), has announced a $10M investment of growth capital from Biospring Partners, a New York based investment firm. The new capital will allow […] Read more

Abzena appoints Stuart Bussell, PhD, as Head of Process Development in San Diego, CA

Cambridge, UK and San Diego, CA,  18 May 2020 – Abzena, the leading Partner Research Organization (PRO) for outsourced solutions integrating gene to GMP services for large molecules and bioconjugates, announced it has appointed Dr. Stuart Bussell as Head of Process Development in San Diego. Stuart has been in the industry for more than 25 years […] Read more

Abzena Appoints Louise Duffy as Senior Vice President and Head of Scientific Project Leadership

Abzena, the leading Partner Research Organization (PRO) for outsourced solutions integrating gene to GMP services for large molecules and bioconjugates, announced it has appointed Dr. Louise Duffy as Senior Vice President and Head of the Scientific Project Leadership. Reporting to Kimball Hall, Chief Operating Officer, and complementing the operational and technical leadership team, Dr. Duffy […] Read more

Information on Abzena’s Response to COVID-19

This page will remain up to date on Abzena’s response to COVID-19 Last updated 16:15 GMT 8th June 2020 Abzena COVID-19 Coronavirus Risk Assessment What are the hazards? Spread of COVID-19 Coronavirus Who might be harmed? • Staff • Visitors to the Abzena premises • Cleaners • Contractors • Delivery Drivers • Vulnerable groups – […] Read more

Information on Abzena’s Response to COVID-19

This page will remain up to date on Abzena’s response to COVID-19 Last updated 15:00 GMT 17th March 2020 The COVID-19 pandemic is a global public health issue of concern to all. I want to update you on our detailed efforts to ensure the health and well-being of our employees, as well as our business […] Read more

Spotlight on Abzena’s Developability Platform during Antibody Engineering & Therapeutics 2019

New service reduces the risk, expenditure and time required for the later stages of antibody development Cambridge, UK, 9 December 2019 – Abzena is showcasing its new Developability Service, enabling biotechnology and pharmaceutical companies to improve lead selection and de-risk cell line development, at Antibody Engineering & Therapeutics 2019 being held 9–13 December, on Booth […] Read more

Abzena Showcases Discovery and Developability Services at PEGS Europe 2019

Bespoke approach generates high affinity antibodies and selects lead candidates with the strongest chances of success in the clinic Cambridge, UK, 18 November 2019 – Abzena is showcasing its Discovery and Developability Services, enabling biopharmaceutical companies to generate high affinity antibodies and select lead candidates with the highest chances of clinical success at the 11th Annual Protein […] Read more

Sonnet BioTherapeutics selects Abzena as clinical stage manufacturing partner for its IL-12-FHAB cytokine-derived therapeutic candidate

PRINCETON, NJ and San Diego, CA, USA 22 October 2019 – Sonnet BioTherapeutics Inc., a clinical stage biopharmaceutical developing innovative targeted biologic drugs, announced today that it has selected Abzena as its manufacturing partner for SON-1010, an IL-12-FHAB cytokine, in preparation for clinical development. SON-1010 uses Sonnet’s proprietary FHAB™ (Fully Human Albumin Binding) technology that leverages […] Read more

Abzena Names Kimball Hall as Chief Operating Officer

Abzena announced today the appointment of Kimball Hall as Chief Operating Officer, adding to the company’s executive leadership team. Ms. Hall will focus on the growth of Abzena as the leading Partner Research Organization (PRO) for outsourced integrated gene to GMP services for large molecules and antibody drug conjugates.  She joins Abzena from Genentech, a […] Read more

Interested in our services? Get In Touch